2,5-Difluoro-benzaldehyde oxime | 915768-14-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,5-Difluoro-benzaldehyde oxime
• 英文别名: 2,5-difluorobenzaldehyde oxime；N-[(2,5-Difluorophenyl)methylidene]hydroxylamine；(NE)-N-[(2,5-difluorophenyl)methylidene]hydroxylamine
• CAS: 915768-14-8
• 化学式: C₇H₅F₂NO
• 分子量: 157.12
• InChiKey: DFMUWVCMTIGSEE-ONNFQVAWSA-N

物化性质

• 沸点：
  207.0±30.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  32.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (7R,9AS)-trans-3-(3-pyrrolidin-1-ylmethyl-phenoxymethyl)-octahydro-quinazolizine dihydrochloride 、 2,5-Difluoro-benzaldehyde oxime 、 2,5-difluorobenzohydroximinoyl chloride 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 生成 (7R,9AS)-trans-(2,5-Difluoro-phenyl)-[7-(3-pyrrolidin-1-ylmethyl-phenoxymethyl)-octahydro-pyrido[1,2-a]pyrazin-2-yl]-methanone oxime
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• ISOXAZOLE-PYRIDINE DERIVATIVES
  申请人：Buettelmann Bernd

  公开号：US20090143371A1

  公开（公告）日：2009-06-04

  The present invention is concerned with isoxazole-pyridine derivatives of formula I wherein X, R 1 to R 6 are as described herein. The compounds are active on the GABA A α5 receptor binding site and useful for the treatment of cognitive disorders, such as Alzheimer's disease.

  本发明涉及式I的异恶唑-吡啶衍生物 其中X，R1至R6如本文所述。这些化合物对GABA A α5受体结合位点具有活性，并可用于治疗认知障碍，如阿尔茨海默病。
• D3 AND 5-HT2A RECEPTOR MODULATORS
  申请人：Gobbi Luca

  公开号：US20100075983A1

  公开（公告）日：2010-03-25

  The present invention provides compounds of the general formula (I) wherein X, n and R 1 are as described herein, as well as pharmaceutically acceptable salts and esters thereof, methods for their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are dual modulators of the serotonin 5-HT 2a and dopamine D 3 receptors, useful in the treatment and/or the prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions.

  本发明提供了一般式(I)的化合物，其中X、n和R1如本文所述，以及其药学上可接受的盐和酯，其制备方法，含有它们的药物组合物以及它们作为药物的用途。本发明的活性化合物是血清素5-HT2a和多巴胺D3受体的双调节剂，在认知障碍、药物成瘾、抑郁症、焦虑症、药物依赖、痴呆症、记忆障碍、包括精神分裂症、情感性精神障碍、双相情感障碍、躁狂症、精神抑郁症以及偏执狂和妄想的精神病等的治疗和/或预防中有用。
• ISOXAZOLO-PYRIDINE DERIVATIVES
  申请人：HOFFMANN-LA ROCHE INC.

  公开号：US20130274468A1

  公开（公告）日：2013-10-17

  The present invention is concerned with isoxazole-pyridine derivatives of formula I wherein X, R 1 to R 6 are as described herein. The compounds are active on the GABA A α5 receptor binding site and useful for the treatment of cognitive disorders, such as Alzheimer's disease.

  本发明涉及公式I中的异恶唑-吡啶衍生物，其中X，R1至R6如此描述。这些化合物在GABA A α5受体结合位点上活性，并且用于治疗认知障碍，例如阿尔茨海默病。
• Azabicyclic 5HT1 receptor ligands
  申请人：Pfizer Inc.

  公开号：US20030181458A1

  公开（公告）日：2003-09-25

  The present invention relates to compounds of the formula 1 These compounds are useful as psychotherapeutic agents.

  本发明涉及公式1的化合物。这些化合物可用作心理治疗剂。
• Aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors
  申请人：FORUM PHARMACEUTICALS, INC.

  公开号：US10370370B2

  公开（公告）日：2019-08-06

  The present invention relates to novel aminobenzisoxazole compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of Alpha7-nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

  本发明涉及适用于作为 Alpha7-nAChR 激动剂或部分激动剂的新型氨基苯并异噁唑化合物及其药物组合物、制备这些化合物和组合物的方法，以及将这些化合物和组合物用于维持、治疗和/或改善认知功能的方法。特别是，将化合物或组合物施用给有需要的患者的方法，例如，有认知缺陷和/或希望提高认知功能的患者，这些患者可从中获益。